The Riverside Company, a private equity investor focused on the smaller end of the middle market, has completed another add-on to its Red Nucleus (RN) platform with an investment in Actando, a global learning organisation that provides technology-enabled learning solutions to life sciences commercial teams that advance critical skills and capabilities across marketing, omnichannel, sales, key account management and market access.
RN is prioritising the development and launch of a unified, robust “essential skills” training offering and has brought in two acquisitions (including Actando) to further that ambition.
Actando marks the third add-on Riverside has completed to Red Nucleus in 2022. Since acquisition, Red Nucleus has grown rapidly and earned a reputation as a leading provider of strategic learning, performance, and process solutions for top global biopharma clients.
